Should you buy AbbVie stock now?
Yes, the technical signal for AbbVie is currently Strong Buy. AbbVie trades at $266.69 as of Oct 7, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 1.943 with falling momentum (signal: 2.048); RSI is at 59.8 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $278.86 points to 4.6% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for AbbVie stock?
The average analyst price target for AbbVie is $278.86. The current price is $266.69, which gives an upside of 4.6%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $250.97 and $306.75.
Is AbbVie a dividend stock?
Yes, AbbVie is a dividend stock with a dividend yield of 2.63%. The latest dividend was $1.73 per share. The latest ex-dividend date (traded without the dividend) was Oct 15, 2026. The payout ratio is 63.7%, which is considered moderate. The next dividend payment is scheduled for Nov 16, 2026.
When does AbbVie pay a dividend in 2026?
AbbVie pays its next dividend on Nov 16, 2026. The latest dividend was $1.73 per share with an ex-dividend date of Oct 15, 2026. The dividend yield is 2.63%. The payout ratio of 63.7% points to moderate dividend coverage.
What is the risk of AbbVie stock?
AbbVie is rated as a stock in the risk category Balanced. the annual standard deviation is 25.3%, which classifies the stock as Balanced.
Is AbbVie overvalued?
AbbVie is considered fairly valued – the price is close to the analyst price target. AbbVie has the following valuation ratios: a P/E ratio of 74.2 (highly valued), a P/S ratio of 7.2, a P/B ratio of 50.5. The stock trades close to the analyst price target and is considered fairly valued.
Is AbbVie overbought?
No, AbbVie is not overbought. RSI is at 59.8 (neutral zone). The technical indicators show: RSI is at 59.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.6% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next AbbVie earnings report?
AbbVie reports its next earnings on October 30, 2026. The stock currently trades at $266.69. With a P/E ratio of 74.2, the market will be watching closely whether earnings meet expectations.
Is AbbVie shorted?
Yes, AbbVie is shorted with 1.2% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying AbbVie stock?
No, insiders are not buying AbbVie shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 1 sales. On a net basis, 8,177,500 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 86,534,575 $ sold. Active sellers include Donoghoe Nicholas, Purdue David Ryan, David Ryan Purdue and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is AbbVie a good stock?
Based on our total score, AbbVie is rated as a good stock with a total score of 62 out of 100. The stock scores above average on value, quality and momentum. The score is made up of Value: 11/100, Quality: 87/100, Momentum: 89/100. In addition: a dividend of 2.63%; technical signal: Strong Buy. Whether AbbVie is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for AbbVie stock?
The outlook for AbbVie based on current data: the average analyst price target is $278.86 (+4.6%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on Oct 30, 2026, which can move the price; the P/E ratio is 74.2 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is AbbVie stock moving?
AbbVie is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can AbbVie go?
The average analyst price target for AbbVie is $278.86, which corresponds to a potential gain of 4.6% from the current price of $266.69. The stock has traded between $189.40 and $269.39 over the last 52 weeks. The price is close to the 52-week high. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can AbbVie fall?
The stock has traded as low as $189.40 over the last 52 weeks — that is 29.0% below the current price of $266.69. The biggest decline (drawdown) in the same period was 29.7% from high to low. Within a year, the price typically swings about ±25.3% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does AbbVie do?
AbbVie is a large pharmaceutical company. It develops, makes, and sells medicines around the world, and it earns money by selling treatments for a range of diseases.
The company was started in 2012 and is based in North Chicago, in the United States. It sells its medicines gl... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - General industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate AbbVie as an investment.
Did AbbVie raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from AbbVie. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is AbbVie making money or losing money?
Yes, AbbVie is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 9.8% — which is moderate. The operating margin (profit before interest and taxes) is 40.0%. At a P/E ratio of 74.2, you currently pay 74.2 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can AbbVie go bankrupt?
The bankruptcy risk of AbbVie is rated as elevated. Altman Z2 (a model for assessing financial distress) is -0.19 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 3,918% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does AbbVie have a lot of debt?
Yes, AbbVie has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 3,918%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can AbbVie service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 9.0x, and net debt equals 2.1 years of earnings (EBITDA).
